The above results show that in LTD, caspase-3 activation requires BAD and BAX, but activation of these proteins usually leads to cell death. This prompted us to investigate whether LTD and apoptosis differ in the mechanisms by which the BAD-BAX-caspase-3 pathway is activated, or in the level of its activation. Dephosphorylation and translocation to mitochondria are critical steps in the activation of BAD during apoptosis. To test whether BAD is activated by similar mechanisms in LTD, we analyzed the level of phosphorylated BAD and the amount selleck inhibitor of BAD in the mitochondrial fraction. In fact, NMDA treatment (30 μM for 5 min as used for LTD

induction) decreased phosphorylated BAD as detected by immunoblotting with an antibody against BAD phosphorylated

at Ser112 (Figures 6A and 6B and Table S2), but the total amount of BAD was not affected (Figure S5A). It is notable that the level of phosphorylated BAD was higher at 30 min than at 10 min after NMDA stimulation (Figures 6A and 6B), suggesting that dephosphorylated BAD was rapidly rephosphorylated after NMDA treatment. Concomitant with the decrease in phosphorylated BAD, there was a transient increase of BAD in the mitochondrial fraction (Figures 6G and 6H). Taken together, these data suggest that BAD undergoes transient dephosphorylation and mitochondrial Roxadustat nmr translocation during LTD. It is known that in apoptosis, BAD can be dephosphorylated by PP1, PP2A and PP2B/calcineurin. We therefore tested whether these phosphatases were also involved in BAD dephosphorylation during LTD. In fact, NMDA-induced

dephosphorylation of BAD was blocked by okadaic acid (50 nM, an inhibitor of PP1 and PP2A) and FK506 (50 nM, an inhibitor of PP2B/calcineurin) (Figures 6C–6F), suggesting that these phosphatases may be responsible for BAD dephosphorylation in LTD. Interestingly, PP1 and PP2B/calcineurin are well known for their roles in the induction of NMDA receptor-dependent LTD, thus the mechanism that activates BAD is in line with the canonical pathway for LTD induction. With respect to the activation tuclazepam of BAX in apoptosis, two processes are known to lead to an increase in active BAX in mitochondrial membranes: translocation of BAX activated in the cytosol to mitochondria, and activation of BAX associated with the mitochondrial membranes by proapoptotic BCL-2 family proteins such as BAD and BID. We measured the amount of active BAX in the whole cell lysates of NMDA-treated neurons (30 μM, 5 min) using immunoprecipitation with the antibody 6A7 that specifically recognizes BAX in the active conformation. It is known that once activated, BAX translocates to mitochondria very efficiently (George et al., 2009). Hence, immunoprecipitation of whole cell lysates with 6A7 measures active BAX predominantly in mitochondria. The amount of active BAX immunoprecipitated by 6A7 from treated cells was higher than that detected in control cells (Figures 6M and 6N; Table S2).